Quest Diagnostics Acquires Fresenius Kidney Testing Assets to Expand Dialysis Services

Quest Diagnostics has announced a deal to acquire kidney disease laboratory testing assets from Fresenius Medical Care, strengthening its portfolio with dialysis-related water testing. As part of the agreement, Quest will take over select assets from Fresenius’ Spectra Laboratories and provide end-stage kidney disease lab services to Fresenius dialysis centers across the U.S.

The acquisition, expected to close in late 2025, will allow Quest to leverage its nationwide laboratory network, reducing transport times and improving testing efficiency. While Quest has been actively acquiring companies, CEO Jim Davis emphasized a more measured approach to dealmaking in 2025, focusing on maximizing returns from past acquisitions while selectively pursuing new opportunities.